Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen
Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen
复制标题
DOI：
10.1016/j.ijid.2016.08.019
复制
发表时间：
2016-10-01
影响因子：
8.4
通讯作者：
Koike, Kazuhiko
中科院分区：
文献类型：
--
作者：
Hirata, Yoshihiro;Serizawa, Takako;Koike, Kazuhiko
目的：目的：探讨埃索美拉唑、阿莫西林和西他夫利联合应用于克拉霉素和甲硝唑一线和二线治疗失败的患者的三线幽门螺杆菌根除治疗的疗效。幽门螺杆菌根除失败的患者前瞻性地接受埃索美拉唑20 mg每日2次、阿莫西林750 mg每日2次和西他夫林100 mg每日2次治疗7天。治疗8-12周后，采用C-13-尿素呼气试验或粪便抗原试验评价根除治疗效果。在意向治疗和符合方案分析中，25例患者成功根除，根除率为83%。在30例患者中未记录具体或显著不良事件。患者特征如性别、体重指数和胃蛋白酶原I/II比值在治疗成功的患者和治疗失败的患者之间没有差异。用埃索美拉唑、阿莫西林和西他沙星进行幽门根除治疗与以前报道的基于西他沙星的三联疗法一样安全有效。(C)2016作者（S）由Elsevier Ltd代表国际传染病学会出版。
Objective: To examine the efficacy of third-line Helicobacter pylori eradication therapy with esomeprazole, amoxicillin, and sitafloxacin for patients with clarithromycin-and metronidazole-based first-and second-line therapy failure.Methods: Thirty patients with first-and second-line H. pylori eradication failure were treated prospectively with esomeprazole 20 mg twice daily, amoxicillin 750 mg twice daily, and sitafloxacin 100 mg twice daily for 7 days. After 8-12 weeks, the outcome of eradication therapy was assessed by C-13-urea breath test or stool antigen test.Results: All 30 patients completed the study. Eradication was successful in 25 patients and the eradication rate was 83% in the intention-to-treat and per-protocol analyses. No specific or significant adverse events were recorded in the 30 patients. Patient characteristics such as sex, body mass index, and pepsinogen I/II ratio did not differ between patients who were treated successfully and those who were not treated successfully.Conclusions: Third-line H. pylori eradication therapy with esomeprazole, amoxicillin, and sitafloxacin is as safe and effective as previously reported sitafloxacin-based triple therapy. (C) 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.